MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy
Authors:
- Silke SchromSSSilke Schrom
- Thomas HebesbergerTHThomas Hebesberger
- Stefanie Angela WallnerSWStefanie Angela Wallner
- Ines AndersIAInes Anders
- Erika RichtigERErika Richtig
- Waltraud BrandlWBWaltraud Brandl
- Birgit HirschmuglBHBirgit Hirschmugl
- Mariangela GarofaloMGMariangela Garofalo
- Claudia BerneckerCBClaudia Bernecker
- Peter SchlenkePeter Schlenke
- Karl KashoferKKKarl Kashofer
- Christian WadsackChristian Wadsack
Open Access
- 20 October 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (21) , 11318
Abstract
Melanomas are aggressive tumors with a high metastatic potential and an increasing incidence rate. They are known for their heterogeneity and propensity to easily develop therapy-resistance. Nowadays they are one of the most common cancers diagnosed during pregnancy. Due to the difficulty in balancing maternal needs and foetal safety, melanoma is challenging to treat. The aim of this study was to provide a potential model system for the study of melanoma in pregnancy and to illustrate melanoma heterogeneity. For this purpose, a pigmented and a non-pigmented section of a lymph node metastasis from a pregnant patient were cultured under different conditions and characterized in detail. All four culture conditions exhibited different phenotypic, genotypic as well as tumorigenic properties, and resulted in four newly established melanoma cell lines. To address treatment issues, especially in pregnant patients, the effect of synthetic human lactoferricin-derived peptides was tested successfully. These new BRAF-mutated MUG Mel3 cell lines represent a valuable model in melanoma heterogeneity and melanoma pregnancy research. Furthermore, treatment with anti-tumor peptides offers an alternative to conventionally used therapeutic options—especially during pregnancy.Keywords
This publication has 50 references indexed in Scilit:
- Intratumoral Heterogeneity as a Therapy Resistance Mechanism2012
- Membrane-active host defense peptides – Challenges and perspectives for the development of novel anticancer drugsChemistry and Physics of Lipids, 2011
- In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacyBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically OrganizedCancer Cell, 2010
- Preparation of Pooled Human Platelet Lysate (pHPL) as an Efficient Supplement for Animal Serum-Free Human Stem Cell CulturesJournal of Visualized Experiments, 2009
- Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cellsTransfusion, 2007
- Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanismsJournal of Cell Biology, 2004
- Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) SignalingJournal of Biological Chemistry, 2003
- The Role of Chemokines in Melanoma Tumor Growth and MetastasisJournal of Investigative Dermatology, 2002
- Melanoma Chondroitin Sulfate Proteoglycan Regulates Matrix Metalloproteinase-dependent Human Melanoma Invasion into Type I CollagenJournal of Biological Chemistry, 2001